VASOCON Drug Patent Profile
✉ Email this page to a colleague
When do Vasocon patents expire, and when can generic versions of Vasocon launch?
Vasocon is a drug marketed by Novartis and is included in two NDAs.
The generic ingredient in VASOCON is antazoline phosphate; naphazoline hydrochloride. There are two drug master file entries for this compound. Additional details are available on the antazoline phosphate; naphazoline hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VASOCON?
- What are the global sales for VASOCON?
- What is Average Wholesale Price for VASOCON?
Summary for VASOCON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Patent Applications: | 2,104 |
| DailyMed Link: | VASOCON at DailyMed |
US Patents and Regulatory Information for VASOCON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VASOCON | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 080235-002 | Mar 24, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | VASOCON-A | antazoline phosphate; naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018746-002 | Jul 11, 1994 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
